Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys. The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Intellia Therapeutics news
05.05.2022
Intellia Therapeutics reported a GAAP loss of $146.872 million for the 3 months of 2022, up 3.19 times from $46.205 million in the previous year. Revenue increased 74.6% to $11.252 million from $6.445 million a year earlier.
Source: 
ir.intelliatx.com
ir.intelliatx.com
10.03.2022
Intellia Therapeutics has received orphan drug status from the FDA for its drug NTLA-5001. The drug is for acute myeloid leukemia. This status provides the company with tax benefits for qualified clinical testing of the drug, a prescription drug tax exemption and seven years of marketing exclusivity following FDA approval.
Source: ir.intelliatx.com
ir.intelliatx.com
24.02.2022
Intellia Therapeutics' GAAP loss for 2021 was $267.892 million, doubling from $134.231 million in the previous year. Revenue decreased 43% to $33.053 million from $57.994 million a year earlier.
Source: ir.intelliatx.com
ir.intelliatx.com
03.02.2022
Intellia Therapeutics is acquiring Rewrite Therapeutics, which is developing new tools for genome editing, including polymerase DNA recording. Intellia will pay $45 million and an additional $155 million when certain milestones are reached.
Source: ir.intelliatx.com
ir.intelliatx.com
General information
| Company name | Intellia Therapeutics |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200 |
| Mailing address | 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 |
| Website | www.intelliatx.com |
English (US) 